NYXH Stock Jumps As ACCCESS Trial De-Risks U.S. Growth Story

Nyxoah SA stocks have been trading up by 15.75 percent following highly promising sleep-apnea therapy trial results.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading NYXH

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Breakthrough ACCCESS study for Nyxoah’s Genio system in complete concentric collapse sleep apnea met both 12‑month co‑primary endpoints, with no device‑related serious adverse events.
ACCCESS trial delivered a 77.2% responder rate on apnea‑hypopnea index, backing a planned FDA PMA supplement that targets a currently untreated U.S. patient group.
Shares of NYXH spiked about 15% after the ACCCESS data, signaling strong trader enthusiasm around potential U.S. label expansion.
Oppenheimer slashed its NYXH price target to $4 from $13 but kept an Outperform rating and reiterated FY26 revenue guidance after reporting €7.7M net revenue.
Cantor Fitzgerald and Piper Sandler cut NYXH targets but maintained Overweight ratings, citing 89 new U.S. accounts, 55 added surgeons, and a solid commercialization ramp.

Live Update At 07:47:35 EDT: On Thursday, September 03, 2026 Nyxoah SA stock [NASDAQ: NYXH] is trending up by 15.75%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For traders watching NYXH, the tape has been tight but telling. Over the last couple of weeks, Nyxoah SA has mostly chopped between $1.55 and $1.65, with recent closes around $1.49–$1.51. That range shows a stock that had been stuck in a low‑volume grind before the latest clinical catalyst hit.

Intraday action paints a different picture. On the ACCCESS headline, NYXH pushed up into the $1.75–$1.80 area, with repeated tests of the $1.78–$1.80 zone. The 5‑minute candles show higher lows from the $1.65s up through the $1.70s, a classic intraday trend day that momentum traders look for.

More Breaking News

Fundamentally, Nyxoah SA is early‑stage, with about $10.02M in trailing revenue and a steep negative pretax margin near -1,065%. The price‑to‑sales ratio around 12.9 and price‑to‑book near 2.6 tell you NYXH trades like a high‑expectation medtech growth story, not a value play. The balance sheet matters here: roughly $48.0M in cash and short‑term investments against about $69.3M in total liabilities and a leverage ratio around 2.4. For traders, that means runway is not infinite, but NYXH still has room to keep pushing commercialization while it waits on the next FDA steps.

Why Traders Are Watching NYXH Momentum

The reason NYXH is suddenly back on a lot of watchlists is simple: data. Nyxoah’s U.S. pivotal ACCCESS study in obstructive sleep apnea patients with complete concentric collapse hit both co‑primary efficacy and safety endpoints at 12 months. That is the sort of binary clinical event that re‑prices a small‑cap medtech name in a single session.

The detail that matters most is the 77.2% responder rate on apnea‑hypopnea index (AHI). For traders, that number is shorthand for “the device works for most patients in this high‑need group.” Add in no device‑related serious adverse events, and NYXH now has a clean safety and efficacy story as it prepares an FDA premarket approval supplement to expand the U.S. label for its Genio system.

This label expansion matters because it targets a patient population that is currently under‑served. If the FDA signs off, NYXH should be able to market Genio to a broader slice of obstructive sleep apnea patients, increasing the total addressable market for Nyxoah SA in the U.S.

The market reaction backed that view. NYXH shares jumped roughly 15% on the ACCCESS announcement, a sharp move for a stock trading around $1.50. That type of spike tells you traders see the ACCCESS data as de‑risking the U.S. story. And yet, even after the pop, NYXH still trades far below the Street’s mean target around $6.01. For day traders, that spread can fuel sympathy runs and squeeze setups whenever new headlines hit.

At the same time, NYXH is not a clean “everything is perfect” story. Oppenheimer came out after Q2, slashing its price target from $13 to $4 while still labeling the stock Outperform and sticking with FY26 revenue guidance. That combination — lower bar now, growth later — is classic for a name resetting expectations but keeping the longer‑term narrative alive.

Cantor Fitzgerald mirrored that tone on NYXH, cutting its target from $11 to $6 but maintaining an Overweight call, pointing to 89 new U.S. accounts and 55 added surgeons in the quarter. Piper Sandler trimmed its NYXH target from $7 to $6, again staying Overweight and noting a solid base for future growth. For traders, the message is clear: Wall Street has turned more realistic on near‑term numbers, but it has not bailed on the story.

Conclusion

NYXH now sits at an interesting crossroads where chart, clinical data, and Street views all collide. On one side, Nyxoah SA is still a loss‑making small‑cap with a negative return on assets around -8.2% and heavy accumulated deficits in retained earnings. The valuation multiples remain rich, and the company will need to keep financing its path to scale. Those are real risks any NYXH trader must respect.

On the other side, the ACCCESS trial changed the fundamental backdrop. A 77.2% responder rate, no device‑related serious adverse events, and a planned FDA PMA supplement under Breakthrough Device Designation all push NYXH closer to a meaningful U.S. expansion. Analysts have cut headline price targets but continue to rate Nyxoah SA as Overweight or Outperform, with an average target far above where the stock trades today.

For active traders, that combination often creates opportunity: a beaten‑down chart, a fresh positive catalyst, and a Street still leaning bullish. The key, as always in the Sykes and StocksToTrade world, is discipline. As Tim Sykes likes to say, “The market doesn’t owe you anything — your edge is in preparation and cutting losses fast.” And as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” NYXH is a name to study, to map out levels, and to trade with a clear plan. This coverage is for educational and research purposes only, and every trader must do their own homework before risking real capital.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!